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ABSTRACT
Male breast cancer (MBC) is a rare disease. Due to its rarity, MBC research and 
clinical approach are mostly based upon data derived from female breast cancer (FBC). 
Increasing evidence indicate that on molecular level MBC may be an heterogeneous 
disease different from FBC.
In order to investigate whether epigenetic signatures could define molecular 
subgroups of MBCs, we performed promoter methylation analysis of genes involved 
in signal transduction and hormone signalling in BRCA1/2 mutation-positive and 
-negative MBCs.
We examined 69 MBCs, paired blood samples, and 15 normal tissues for promoter 
methylation of hTERT, ESR1, RASSF1, AR, MYC and WNT1 genes.
MBCs showed higher gene promoter methylation levels compared to paired blood 
and normal breast samples. Significantly higher RASSF1 methylation levels were 
observed in association with BRCA1/2 mutations, HER2 expression and high tumor 
grade. Significantly higher AR methylation levels were observed in BRCA1/2 wild-type 
cases and higher WNT1 methylation levels in PR negative cases.
Overall, our results indicate that alterations in gene methylation profiles are 
common in MBC and that methylation pattern of tumor-associated genes may allow 
for the identification of MBC molecular subgroups, that could have implications in 
clinical management of MBC patients.
INTRODUCTION
Male breast cancer (MBC) is a rare disease, 
representing less than 1% of all breast cancers and 
less of 1% of all male tumors [1]. Despite the rarity, 
morbidity and mortality in MBC patients is a serious 
concern.
MBC shares some similarities with post-menopausal 
ER-positive female breast cancer (FBC). Increasing 
evidence indicate that, on clinical and molecular level, 
MBC may be a heterogeneous disease, different from FBC 
[2–4]. Compared to FBC, MBC occurs later in life, with 
higher stage, lower grade and more estrogen/progesterone 
receptor (ER/PR) positivity [5–6].
MBC research and patient management are mostly 
based upon data derived from its largely known female 
counterpart. To date, mortality and survival rates for 
patients with MBC have improved less over time than for 
patients with FBC [5]. These data highlight the need to 
identify specific biological markers for MBC.
Aberrant DNA methylation may play a role in the 
initiation of cancer, tumor progression and response to 
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treatment [7]. Promoter methylation of genes involved 
in cancer development and progression, such as tumor 
suppressors, cell cycle regulators and transcription factors, 
are frequently reported aberrantly methylated in FBC 
[8–9].
Different studies have suggested that aberrant 
methylation at specific gene promoter regions may 
contribute to the malignant phenotype and could be used 
as biomarkers for diagnosis at an early stage and prediction 
of prognosis in breast cancer [10–12]. Moreover, 
there are growing evidence that the characterization 
of tumor-specific methylation profiles may allow for 
the identification of specific breast cancer subtypes. In 
particular, methylation analysis of FBCs allowed for the 
identification of gene methylation profiles associated with 
molecular subtypes via ER/PR, HER2 and BRCA mutation 
status [13–15].
DNA methylation abnormalities may occur in tissue 
adjacent to the tumor, that is considered histologically 
normal. A limited number of studies have showed that 
promoter methylation status of specific genes in normal 
tissue correlate with that found in tumor sample [16–
17]. It is also becoming increasingly apparent that gene 
methylation in blood DNA of breast cancer patients may 
be a part of a disease predisposition mechanism [18–19]. A 
concordance in the promoter methylation patterns between 
blood DNA from breast cancer patients and corresponding 
tumors has been reported [20–21].
To date the contribution of aberrant DNA 
methylation in the pathogenesis of MBC has been 
investigated only in few studies [22–25]. These studies 
showed that methylation of genes involved in DNA repair 
and cell growth and differentiation may play a role in 
MBC and may be associated with aggressive phenotype 
and worse disease specific survival [22, 25].
We previously showed that BRCA mutation positive 
and BRCA mutation negative MBC cases display different 
phenotypic features, and in particular we identified a 
specific BRCA2-associated MBC phenotype characterized 
by higher tumor grade compared with MBC from the 
general population [26–28]. Recently, it has been reported 
that BRCA2-associated MBCs are characterized by 
elevated tumor methylation [25].
In this study we examined methylation profiles of 
BRCA mutation positive and BRCA mutation negative 
MBCs by performing promoter methylation analysis of a 
panel of breast cancer-related genes, in order to investigate 
whether epigenetic signatures could define molecular 
subgroups of MBCs.
In particular, we examined promoter methylation 
status of genes involved in signal transduction and 
hormone signalling, including AR, ESR1, hTERT, MYC, 
RASSF1 and WNT in male breast tumors, paired blood 
samples and normal tissues.
Our specific aims were to examine the level of 
methylation of important breast cancer genes in a series of 
MBC cases all characterized for BRCA1/2 mutation status 
and to identify potential molecular subgroups defined 
by their methylation patterns with clinical-pathologic 
correlation.
RESULTS
Clinical-pathologic characteristics of MBC cases
All cases included in this study were characterized 
for BRCA1/2 germline mutations, the major genetic risk 
factor for MBC, and for the main clinical-pathologic 
features including: family and personal history of cancer, 
ER, PR, HER2 and Ki67/MIB1 expression and tumor 
grade (G). As shown in Table 1, 26% of MBC patients 
have family history of breast/ovarian cancer, 29% have 
personal history of cancer other than breast cancer and 
14.5% are positive for BRCA1/2 mutations. The majority 
of MBC cases are ER and PR positive (90.8% and 83%, 
respectively), HER2 and Ki67/MIB1 negative (84.2% 
and 61.7%, respectively) and have intermediate/moderate 
tumor grade (G2) (52.4%).
Gene promoter methylation analysis in tumor 
and normal tissues
Using candidate-gene approach, we examined 
the promoter methylation level of AR, ESR1, hTERT, 
MYC, RASSF1 and WNT1 in 69 male breast tumors and 
corresponding blood samples, 7 normal breast tissues and 
8 normal lymph node samples.
Compared with the median methylation levels of 
each gene in normal breast samples, 63/67 (94%) tumor 
samples showed higher methylation level for AR, 53/67 
(79.1%) for RASSF1, 44/69 (63.8%) for hTERT, 37/69 
(53.6%) for MYC, 36/68 (52.9%) for WNT1, and 35/68 
(51.5%) for ESR1. Methylation levels varied among genes 
with predominantly high methylation levels in hTERT, for 
which levels were up to 72% in tumors and 26% in normal 
breast samples (Figure 1A).
Overall, tumors showed higher median methylation 
levels compared with normal breast tissues (Table 2). A 
statistically significant differences emerged for hTERT 
(p=0.0008) when we compared methylation levels of 
tumors with lymph node samples. AR median methylation 
levels in tumors were statistically significant higher 
compared to those observed in normal breast tissues and 
lymph node samples (p=0.0009 and p=0.003 respectively). 
Statistically significant differences emerged between 
median methylation levels of tumors and paired blood 
samples (Table 2).
Cluster analysis
Hierarchical cluster analysis was performed on 
64 male breast tumors, for which data on promoter 
methylation levels of all genes analyzed were available 
(Figure 1B). Two groups of clustered MBC cases 
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emerged, one group characterized by high (≥30%) 
hTERT promoter methylation levels and a second group 
characterized by moderate (≥20% and >30%) and low 
(<20%) hTERT promoter methylation levels. Notably, 
the majority of BRCA1/2 mutation carriers (8/10) were 
included in the groups of cases characterized by high 
and moderate hTERT promoter methylation levels 
(Figure 1B).
Table 1: Clinical-pathologic characteristics of the 69 male breast cancer cases analyzed
CLINICAL-PATHOLOGIC CHARACTERISTICS N(%)
Family history of breast/ovarian cancer  
Negative 51(74.0)
Positive 18(26.0)
Tot 69
Personal history of other cancer  
Negative 49(71.0)
Positive 20(29.0)
Tot 69
BRCA1/BRCA2 status  
BRCA1 mutated 2(2.9)
BRCA2 mutated 8(11.6)
BRCA1/BRCA2 wild-type 59(85.5)
Tot 69
ER  
Negative (≤10%) 6(9.2)
Positive (>10%) 59(90.8)
Tot 65
PR  
Negative (≤10%) 11(17.0)
Positive (>10%) 54(83.0)
Tot 65
HER2  
Negative (≤25%) 48(84.2)
Positive (>25%) 9(15.8)
Tot 57
Ki67/MIB1  
Negative (≤20%) 37(61.7)
Positive (>20%) 23(38.3)
Tot 60
Hystological grade  
G1 13(20.6)
G2 33(52.4)
G3 17(27.0)
Tot 63
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Association between gene methylation and 
clinical-pathologic characteristics of MBC
For each gene, association between median promoter 
methylation levels and relevant clinical-pathologic 
characteristics of each MBC case was evaluated. As shown 
in Table 3, significantly higher RASSF1 methylation levels 
were observed in cases positive for BRCA1/2 mutation 
(p=0.008), HER2 expression (p=0.01), and with high 
tumor grade (G3) (p=0.008). Significantly higher AR 
methylation levels were observed in BRCA1/2 wild-type 
cases (p=0.016) and higher WNT1 methylation levels were 
observed in PR negative cases (p=0.014).
DISCUSSION
In order to investigate whether epigenetic signatures 
could define molecular subgroups of MBCs, we examined 
methylation profiles of MBC cases, characterized for 
BRCA1/2 mutation status, by performing promoter 
methylation analysis of genes representative of cellular 
pathways known to be involved in breast cancer. We 
also analyzed possible correlations between methylation 
levels of these genes and the main clinical-pathologic 
characteristics of MBC cases.
Promoter methylation status was assessed by 
pyrosequencing, a technique that offers a unique 
opportunity to quantify, site-specifically, the methylated 
fraction in CpG site. This method has been shown as the 
most suitable to determinate very low methylation levels 
and to discriminate between small differences in the 
methylation status of gene promoters [29].
Methylation analysis was performed in male breast 
tumors, paired blood samples, normal breast tissue and 
lymph nodes samples. The analysis results allowed for the 
identification of tumor specific methylation profiles.
In agreement with previous papers [22–25], our 
results showed that high methylation levels in promoter 
regions of candidate genes are frequently observed in male 
breast tumors. Notably, in our study we were able to obtain 
and compare data on methylation in male breast tumors 
and matched blood samples. At present only four studies 
Figure 1: (A) Distribution of the methylation levels in different tissue samples from male breast cancer cases. Boxplots show comparison 
of median methylation levels of hTERT, WNT1, AR, MYC, ESR1 and RASSF1 genes in blood, lymph node, normal breast and tumor breast 
samples. (B) Unsupervised hierarchical clustering analysis of promoter methylation levels of 6 genes in 64 male breast turmors.
Oncotarget19787www.oncotarget.com
examined methylation in MBC but none has investigated 
methylation in DNA from paired blood samples [22–
25]. Here we showed that compared with paired blood 
samples, tumors displayed significant higher methylation 
levels for all the genes analyzed. Further studies on DNA 
methylation in blood and normal tissues of MBC patients 
and population controls should be performed in order to 
investigate a possible role of methylation as marker for 
MBC risk and early diagnosis.
In our study, AR, RASSF1 and hTERT were the 
genes that most frequently showed higher methylation 
levels in tumor compared to normal breast tissues, with 
AR showing a statistically significant difference. To our 
knowledge, AR and hTERT promoter methylation has not 
been previously investigated in MBC.
We observed high promoter methylation levels of AR 
in the vast majority (94%) of MBC cases examined. AR is 
known to be involved in a complex network of signaling 
pathway that collectively regulate cell proliferation [30]. 
Hypermethylation of AR promoter was reported to be 
associated with reduced AR expression in breast cancer 
cell lines [31]. Specifically for MBC, AR expression has 
been reported as a positive prognostic marker for overall 
and disease-free survival [32]. Notably, AR has also 
received attention as a valid drug target in MBC patients 
[33]. Overall, our data add further evidence to a relevant 
role of AR in MBC and suggest that methylation status 
of AR promoter may eventually impact on the clinical 
management of MBC patients.
We also observed high promoter methylation level 
of hTERT in a large percentage of male breast tumors 
(63.8%) and, by cluster analysis, two subgroups of MBC 
cases were identified based on methylation levels of 
hTERT. hTERT encodes for the human telomerase reverse 
trancriptase (hTERT), the catalytic subunit of telomerase, 
and plays a key role in telomerase activity [34–35]. 
The telomerase activity is almost silenced in normal 
somatic cells, but activated in more than 90% of cancers 
[36]. Increased expression of the protein associated to 
hypermethylation of regulatory region of hTERT has been 
reported in cancer cells [37–38]. We showed that a large 
percentage of male breast tumors are characterized by high 
promoter methylation level of hTERT thus suggesting that 
telomerase activity may be altered in MBC. Functional 
studies would be needed to support this hypothesis.
In agreemet with previous studies [23, 25], we 
showed that RASSF1 promoter methylation is frequently 
observed in MBCs. Furthermore, we found associations 
between RASSF1 promoter methylation and aggressive 
tumor characteristics, such as HER2 expression and 
high tumor grade (G3). The association between 
RASSF1 methylation and adverse phenotypic features in 
MBC may indicate RASSF1 as a prognostic biomarker 
in MBC.
ESR1 promoter methylation has been reported as 
an independent biomarker for aggressive MBC, due to its 
correlation with high mitotic count and high tumor grade 
[22]. In our MBC series no significant correlation between 
ESR1 promoter methylation status and clinical-pathologic 
characteristics of tumors emerged, however higher ESR1 
methylation levels were observed in cases with biological 
variable indicative of a more aggressive phenotype, such 
as ER-, PR-, G3, Ki67/MIB1+.
Although knowledge on methylation profiles 
of MBC is increasing, specific comprehension on 
methylation profiles of MBCs associated with BRCA1/2 
mutation status is still incomplete. In our MBC series, 
statistically significant differences in gene-specific 
methylation profiles related to BRCA1/2 mutation status 
were observed. In particular, according to Deb et al 2017 
[25], significantly higher promoter methylation levels of 
RASSF1 were associated with BRCA1/2 positive status. 
In addition, we showed that higher AR methylation levels 
were found in BRCA1/2 wild-type cases. These findings 
add new molecular evidence on the distinction between 
sporadic and hereditary MBC.
Table 2: Gene-promoter median methylation levels in breast tumor, normal breast, normal lymph-node and blood 
samples from male breast cancer patients
 BREAST TUMOR (N=69)
NORMAL 
BREAST (N=7)
NORMAL 
LYMPH-NODE 
(N=8)
BLOOD (N=69) ap T vs N ap T vs L ap T vs B
hTERT 27.00 (69) 18.75 (7) 8.50 (8) 6.75 (69) 0.11 0.0008 <0.0001
AR 11.70 (67) 4.20 (6) 5.85 (6) 10.00 (67) 0.0009 0.003 0.0006
WNT1 6.75 (68) 6.50 (7) 10.13 (8) 3.75 (68) 0.27 0.02 <0.0001
MYC 3.25 (69) 3.00 (6) 2.13 (8) 1.75 (69) 0.67 0.13 <0.0001
RASSF1 5.75 (67) 3.00 (3) 5.00 (6) 2.75 (67) 0.54 0.38 <0.0001
ESR1 6.25 (68) 5.75 (7) 4.25 (8) 2.75 (68) 0.49 0.29 <0.0001
a p-values from non-parametric Mann-Whitney-Wilcoxon test. In bold p-value <0.05, considered statistically significant. 
T: breast tumor; N: normal breast; L: lymph node; B: blood.
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In summary, our results indicate that alterations 
in gene methylation profiles are common in MBC and 
that tumor-associated gene methylation patterns may 
identify specific MBC subgroups related to BRCA1/2 
mutation status and clinical-pathologic characteristics. 
Overall these findings may allow for the identification 
of molecular predictive and prognostic biomarkers and 
may have implications for clinical management of MBC 
patients. Further studies, particularly on series of MBCs 
with adequate follow-up, are needed in order to support 
the clinical relevance of gene promoter methylation as 
potential molecular biomarkers.
MATERIALS AND METHODS
Patient samples
DNA from tumor and paired blood samples of 69 
MBCs, 8 normal lymph nodes and 7 normal male breast 
tissues was analyzed. All cases were recruited from a 
population-based series of MBC and were characterized 
for BRCA1/BRCA2 mutations and for main clinical-
pathologic features including: family and personal history 
of cancer, ER, PR, HER2 and Ki67/MIB1 expression, and 
tumor grade (G).
Table 3: Associations between gene methylation levels and clinical-pathologic characteristics in male breast tumors
 hTERT ESR1 RASSF1 AR MYC WNT1 
 %a pb %a pb %a pb %a pb %a pb %a pb
Family history of 
breast/ovarian cancer             
Negative 25.5
0.7 
6.3
0.7 
5.6
0.8 
12
0.4 
3.3
0.7 
6.5
0.2 
Positive 32.2 5.8 6 11.7 2.8 7.8
Personal history of 
other cancer             
Negative 30.2
0.12 
6.4
0.2 
6
0.5 
11.7
0.2 
4
0.1 
6.5
0.8 
Positive 17.7 3.8 4.8 13 3.8 6.8
BRCA1/2 status             
BRCA1/2 mutated 39.7
0.076
6.8
0.07 
9.1
0.008 
5.2
0.016 
4.3
0.2 
6.8
0.5 
BRCA1/2 wild-type 25.1 5.8 4.7 10.4 3.3 5.9
ER             
Negative 25.0
0.4 
6.8
0.3 
8.9
0.6 
4.6
0.6 
3.8
0.5 
7.3
0.6 
Positive 29.3 5.8 5.6 10 3.3 6.8
PR             
Negative 45.5
0.16 
6.6
0.3 
5.5
0.16 
8.8
0.9 
3.5
0.5 
8.5
0.014 
Positive 26.3 5.8 6.5 10.0 3.3 5.5
HER2             
Negative 28.0
0.5 
6.2
0.3 
4.8
0.01 
10.0
0.6 
3.5
0.08 
6.8
0.1 
Positive 21.6 4.1 7.4 11.2 2.3 5.1
Ki67             
Negative 25.3
0.6 
4.9
0.7 
5.5
0.4 
10.0
0.6 
3.25
0.5 
6.8
1 
Positive 30.3 6.3 6.0 10.7 3.25 6.9
Hystological grade             
G1+G2 29
0.9 
5.8
1
4.8
0.008 
10.7
0.3 
3.4
0.1 
6.5
0.2 
G3 28.3 6.0 7.8 8.4 2.2 7.9
a%: median of methylation for each gene; bp value derived from Kruskal-Wallis test. In bold p-value <0.05, considered 
statistically significant.
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The entire BRCA1 and BRCA2 coding sequences 
were analyzed mostly by automated Sanger sequencing, 
otherwise by a combination of protein truncation test 
(PTT) and single-strand conformation polymorphism 
(SSCP). All cases were retested for BRCA1/2 mutations 
using Next Generation Sequencing. Cases were also 
tested by MLPA for the detection of large genomic 
rearrangements [26, 39–40].
The expression of ER, PR, and Ki67/MIB1 was 
scored based on the percentages of positive nuclei (ER/
PR positive if >10%; Ki67 high if >20%) over the total 
number of counted cancer cell nuclei. HER2 expression 
was scored according to the percentage of positive tumor 
cells as: 1+ (<25%), 2+(25-50%), 3+ (>50-75%) and 4+ 
(>75%). HER2 positivity was defined as a score of 2+ 
using immunohistochemistry (IHC) test, or amplification 
shown by fluorescence in situ hybridization (FISH), in 
equivocal cases [41–42].
For some cases the amount of DNA was inadequate 
to carry out all molecular analyses.
The participants signed an informed consent form 
with a detailed description of the study protocol. The study 
was approved by The Local Ethical Committee (Sapienza 
University of Rome, Prot 669/17).
DNA extraction and methylation analysis
Genomic DNA was isolated from blood using 
ReliaPrepTM Blood gDNA MiniPrep System (Promega) 
according to the manufacturer’s instructions. DNA from 
tumor, normal breast and lymph node samples was 
extracted from formalin fixed paraffin-embedded (FFPE), 
using 5-10um thick sections, by EpiTect Plus FFPE lysis 
kit (Qiagen) according to the manufacturer’s instructions. 
Tumor DNA was extracted from microdissected tumor 
samples. Microdissection assures that each sample 
contains at least 60-70% of tumor cells.
DNA bisulfite modification was performed using 
EpiTect Plus DNA Bisulfite kit (Qiagen) according to the 
manufacturer’s instructions.
Promoter methylation of AR, ESR1, hTERT, MYC, 
RASSF1 and WNT1 genes for a total of 26 CpG sites, was 
evaluated.
Methylation analysis was performed by 
pyrosequencing, a highly sensitive and reproducible 
method, which provides absolute quantitative information 
on bases at each CpG site analyzed, using Pyromark 24Q 
(Qiagen) platform. Pyrosequencing for DNA methylation 
analysis was performed following protocol previously 
described [29].
Specific pyrosequencing primers were used to assay 
on consecutive series of 3 to 5 CpG sites in the promoter 
region of the selected genes. For hTERT gene, primer 
for PCR amplification and sequencing were designed 
using the PyroMark Assay Design 2.0 software. Primers 
were designed to amplify fragments of about 90bp 
because of possible fragmentation of DNA isolated from 
FFPE samples. For the other five genes commercially 
available assays, including primers for amplification and 
sequencing, were used (Qiagen).
The degree of methylation at each CpG position 
in a sequence was determined from the C/T ratio. 
Target CpGs are evaluated by converting the resulting 
pyrograms to numerical values for peak heights. For each 
analyzed methylation levels were expressed as median 
of methylation percentage at all CpG sites gene both in 
tumors and normal tissues.
Statistical analysis
The non-parametric Mann-Whitney-Wilcoxon test 
was used to compare DNA methylation values in normal 
(blood, lymph node and breast tissue) and tumor samples.
Unsupervised hierarchical clustering was performed 
to analyze relevant clusters and co-methylation. 
Dendrograms and heatmap were then generated using 
Euclidean distance matrix and complete linkage.
To assess associations between methylation levels 
for each gene and clinical-pathologic features in the tumor 
sample group, the Kruskal–Wallis test was used.
For all the analyses, a p-value <0.05 was considered 
statistically significant. All statistical analyses were 
performed with the R software (www.r-project.org).
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